CATEGORY

VIEW/download

Systematic screening of generic drugs for progressive multiple sclerosis identifies clomipramineas a promising therapeutic. FaissnerS et al Nat Commun2017

pubmed

A staged screening of registered drugs highlights remyelinatingdrug candidates for clinical trials. Eleuteri et al, Sci Rep 2017

 pubmed 

 Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial.
Green AJ et al. Lancet 2017

 pubmed

Unexpected additive effects of minocycline and hydroxychloroquine in models of multiple sclerosis: Prospective combination treatment for progressive disease?
Faissner S et al,  Mult Scler J 2017

pubmed

Activation of Glucagon-Like Peptide-1 Receptor Promotes Neuroprotection in Experimental Autoimmune Encephalomyelitis by Reducing Neuroinflammatory Responses.
Lee CH et al. Mol Neurobiol 2017

pubmed

A staged screening of registered drugs highlights remyelinating drug candidates for clinical trials.
Eleuteri et al. Sci Rep 2017

pubmed

Rapid and efficient generation of oligodendrocytes from human induced pluripotent stem cells using transcription factors.
Ehrlich M et al, PNAS 2017

pubmed

Clobetasol promotes remyelination in a mouse model of neuromyelitis optica.
Yao X et al. Acta Neuropathol  Commun 2016

pubmed

Clobetasol and Halcinonide Act as Smoothened Agonists to Promote Myelin Gene Expression and RxRγ Receptor Activation.
Porcu G et al. PlosOne 2015

 pubmed